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Epigenetic modifications influence gene expression and thereby play a pivotal role in 
development and disease. Misregulation and mutations in the DAX-1 gene, or Dosage-Sensitive 
Sex Reversal, Adrenal Hypoplasia Congenita, Critical Region on the X chromosome, gene 1, have 
been implicated in Adrenal Hypoplasia Congenita (AHC) and Dosage Sensitive Sex Reversal 
(DSS). The orphan nuclear hormone receptor DAX-1 is expressed predominantly in tissues such 
as the testes, ovaries, breast, adrenal cortex, and lung. Critically, DAX-1 may serve as an indicator 
of aberrant growth in these tissues. Here we hypothesize that DAX-1 is epigenetically regulated, 
specifically in cancer cells, thereby reducing its expression. In a survey of several human cancer 
cell lines, the methylation status of the promoter region of DAX-1 was investigated in order to 
determine whether epigenetic control played a role in repressing DAX-1 gene expression. Through 
molecular techniques such as qPCR and western blots, differential expression of DAX-1 in human 
cell lines was confirmed. Additionally, methylation specific restriction enzyme analysis and 
bisulfite sequencing identified the location of methylation in breast, adrenal, lung, liver, and kidney 
cancer cell lines. Following these experiments, a correlation of the methylation status of the DAX-
1 promoter and DAX-1 expression is evident. In tandem with bisulfite sequence analysis, 
chromatin immunoprecipitation experiments elucidated a primary region of interest in which 
methylation may be critical to the silencing of DAX-1 gene expression. Centered around the 
transcriptional start site, a stark difference in methyl binding protein occupancy between cancerous 
and noncancerous breast tissue was identified and likely plays a critical role in gene repression via 
methylation. Ultimately, this research aims to elucidate the role of epigenetic regulation in gene 
expression as well as further our understanding of the role of DAX-1 in human cancers. 
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Chapter 1: Introduction 
The epigenome is a collection of heritable modifications to DNA that results in genotypic 
and phenotypic variability. Physiologically, these modifications are common occurrences 
observed between different types of cells within the body. However, aberrant epigenetic mutations 
can lead to disease and in some cases, be used as an identifier of cancer. Studies of epigenetics 
have elucidated a great deal of information about both the genesis of disease as well as its 
heritability. Specifically, cancer epigenetics is a popular new topic on the forefront of scientific 
research. However, before understanding the mutations and possible misregulation brought forth 
through epigenetic modifications, it is critical to understand the basic process. My thesis focuses 
on the epigenetic regulation of the DAX-1 (Dosage-Sensitive Sex Reversal, Adrenal Hypoplasia 
Congenita, Critical Region on the X chromosome, gene 1) gene and the fundamental role of 
epigenetics in gene expression. Central to this thesis research is understanding the gene, its current 
implications on growth and development, and how epigenetics may be playing a significant role. 
I have investigated key commonalities found in breast, prostate, lung, adrenal, and liver cancer 
(Conde et al., 2004; He et al., 2008; Heskett, 2014; Jiang et al., 2014; Kudryavtseva et al., 2018; 
Kumata et al., 2018). All of these forms of cancer express, to varying degrees, the DAX-1 gene. 
Nevertheless, the exact role DAX-1 plays in each of these cancers is not yet fully understood. The 
goal of this thesis project is to investigate the epigenetic mechanisms that control DAX-1 gene 





Epigenetic modifications are an important mechanism that regulate gene expression during 
development, but these modifications also play a key role in diseases such as diabetes, 
cardiovascular disease, and cancer. Before delving into how epigenetics plays a role in 
development and disease, it is important to first define epigenetics, epigenetic modifications, and 
the epigenome. Epigenetics has been of prominent interest for the past few decades, however, an 
agreed upon definition has yet to emerge. Starting in the late 1950s, epigenetics was defined as the 
study of genotypes that lead to specific phenotypes in development (Bird, 2002, 2007). However, 
more recently in the 1990s, a new interpretation arose when Arthur Riggs and colleagues defined 
epigenetics as the heritable modifications to genes that are beyond what the DNA encrypts (Bird, 
2007; Russo et al., 1996; Waddington, 2014). Further debates came in the early 2000s, as 
epigenetics took on a new form as a biomarker and possible means of diagnosis. Alternatively, 
epigenetics was also defined as “all the heritable changes in gene regulation other than nucleotide 
sequence and chromatin organization that depend on the DNA sequences itself” (Abi Khalil, 2014; 
Egger et al., 2004; Rodenhiser & Mann, 2006). The increasing diversity in defining epigenetics 
has led some scientists to call for a new ‘standard’ that all epigeneticists can utilize. In 2007, a 
modified statement was suggested, one that encompassed many schools of thought: “the structural 
adaptation of chromosomal regions so as to register, signal or perpetuate altered activity state” 
(Bird, 2007). Although discrepancies continue, the field of epigenomics has begun to answer 
questions regarding heritable traits. Newer interpretations have evolved and epigenetics is quickly 
becoming the science that can explain how cells adapt to and are altered by their environment 
through modifications of the gene that lead to phenotypic differences not expressed in the genotype 
(Ordovás & Smith, 2010; Turan et al., 2010). For the purpose of the research outlined in this thesis, 
13 
 
I will focus on the resulting epigenetic modification, rather than the origin of that change. 
Epigenetic modifications are post-translational changes in the DNA sequence that control gene 
expression. There are three primary classes of epigenetic modification mechanisms in human cells: 
DNA methylation, histone modification, and micro-RNA based mechanisms. All three 
mechanisms are often interrelated and pivotal to cell differentiation, gene activity, and aging (Abi 
Khalil, 2014; Jintaridth & Mutirangura, 2010; Kwabi-Addo et al., 2007; Murgatroyd & Spengler, 
2011). 
As fundamental mechanisms to gene expression, epigenetic modifications are heritable, 
occasionally reversible, and have been tied to disease. Among some of the more studied cases, 
epigenetics has been associated with developmental diseases, mental illness, cardiovascular 
disease (CVD), and cancer (Ball et al., 2009; Bird, 2002; Brown et al., 2008; Eckhardt et al., 2006; 
Halušková, 2009; Hansen et al., 2011; He et al., 2008; Jintaridth & Mutirangura, 2010; Kerachian 
et al., 2020; Kudryavtseva et al., 2018; Kwabi-Addo et al., 2007; Manel, 2008; Manoochehri et 
al., 2016; Martin et al., 2011; Murgatroyd & Spengler, 2011; Rakyan et al., 2004; Robertson, 2005; 
Suzuki & Bird, 2008; van IJzendoorn et al., 2011; E. M. Wong et al., 2020; Zhu & Yao, 2007). 
Early development is heavily impacted by epigenetic marks that influence gene expression and 
cell differentiation (Cedar & Bergman, 2011). Critical cellular processes, such as hematopoietic 
cell development, are mediated by epigenetic changes that include histone deacetylation and 
demethylation. These modification patterns determine a cell's fate to either remain in a pluripotent 
state or commit to a specific cell type. For example, the decision required for a cell to progress 
towards myeloid versus lymphoid differentiation depends on the expression of the V(D)J gene 
segments and the ‘assembly’ of antibodies through V(D)J recombination in both B and T cells. 
Notably, this process is regulated by histone activation (Cedar & Bergman, 2011). In neurological 
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development, epigenetic alteration of gene expression in early years has been shown to impact 
brain function and mental illness later in life (Murgatroyd & Spengler, 2011). Similar to the 
differentiation produced by V(D)J recombination, neurons contain the same DNA but carry out 
diverse functions due to differential gene expression. Pre- and postnatal development is influenced 
by environmental conditions. Therefore, gene expression can be mediated by epigenetic 
modifications brought about not only through natural mechanisms, but also external influences 
such as maternal care or early life adversity and stress. Such variations to the epigenome caused 
by gene silencing or inappropriate expression have been identified in neurodegenerative diseases, 
mental retardation, and schizophrenia. Still, the impacts of epigenetic modification and 
dysregulation are not limited to developmental diseases. As the global leading cause of death, 
cardiovascular disease is a prominent target for therapeutic research (Cardiovascular Diseases, 
n.d.). Previous studies have linked all three forms of epigenetic modifications (methylation, 
histone modification, and micro-RNA based mechanisms) to various cardiovascular diseases 
including heart hypertrophy, heart failure, arrhythmias, and vascular diseases (Abi Khalil, 2014). 
In some instances, the epigenetic involvement is more direct, impacting inflammation and vascular 
function. In other cases, the role of epigenetics is more pertinent through the lens of increased risk 
factors (Abi Khalil, 2014; Ordovás & Smith, 2010). Environmental and behavioral factors such as 
pollution, smoking, stress, nutrition and circadian rhythm have been shown to influence the risk 
and progression of CVDs.  
Although the correlation between epigenetics and disease has been established, uncertainty 
remains around whether epigenetics is a precursor to disease or the result of a disease (Bell & 
Spector, 2011; Martin et al., 2011). It is evident that aberrant epigenetic modifications overlap 
with disease; therefore an addendum to the definition of epigenetics is inevitably required: “one 
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caused by a stable alteration in the epigenetic state of a gene (epimutation) without any 
contributory genetic mutation” (Martin et al., 2011). Although this may seem to lead towards a 
causal relationship between epigenetics and disease, this is not the case. Environment plays a 
fundamental role in development, and epigenetics is the mechanism for rapid cellular adaptation 
(Bell & Spector, 2011; Murgatroyd & Spengler, 2011; van IJzendoorn et al., 2011). Therefore, it 
may be the environment or the disease that leads to the aberrant modifications, and not the other 
way around. This line of behavioral epigenetic research can often unravel into a question of nature 
versus nurture, and which came first. Regardless, the theme remains that epigenetics is prevalent 






Figure 1.1 The interconnection of genetic, epigenetic, the environment and phenotypic 
results. Figure adapted from van IJzendoorn et al., 2011 depicting the theory of behavioral 






The focus of this thesis research is on one particular type of epigenetic modification: DNA 
methylation. DNA methylation is the process by which a methyl group is transferred onto the C5 
position of a cytosine (Moore et al., 2013; Zeisel, 2009). The transfer can be done by DNA 
Methyltransferases (DNMTs), methyl-CpG binding domain proteins, and the Kaiso family of 
proteins (Fournier et al., 2012). The Kaiso family of proteins are unique in their ability to bind 
both methylated CpG-containing DNA sequences, as well as non-methylatable regions without 
CpG islands. Kaiso family proteins can bind to sequence-specific methylated regions of promoters 
and thereby repress transcription (Fournier et al., 2012; Sasai et al., 2010). Cytosine DNA 
methylation is crucial to our understanding of human development as it is the only known DNA 
modification fundamental to mammalian growth (Jones & Takai, 2001; Robertson, 2005). 
Following the completion of the Human Genome Project in 2003, new attention was granted to 
the Human Epigenome Project because it became clear that epigenetic marks are heritable and 
contribute significantly to embryonic development and phenotype expression (Rakyan et al., 2004; 
Robertson, 2005). Functionally, DNA methylation often results in the silencing of gene expression 
and promoter activity (Figure 1.2) (Bird, 2002; Moore et al., 2013; Suzuki & Bird, 2008; van 





Figure 1.2 The biochemical reaction of cytosine methylation in DNA results in the silencing 
of gene expression. Figure adapted from van IJzendoorn et al., 2011 and Zeisel, 2007; the addition 
of CH3 to a cytosine molecule via a methyl binding protein (MBP) prevents the transcription factor 





This epigenetic mark caused by DNA methylation goes beyond differential expression of 
genes necessary during development and underlies human disease, X-chromosome inactivation, 
and genomic imprinting disorders (Egger et al., 2004; Halušková, 2009; Heard et al., 1997; E. Li 
et al., 1992, 1993; Robertson, 2005; Weber et al., 2007). Looking more closely at some of the 
conditions mentioned above, methylation has a prominent place in disease. Specifically in CVD, 
hypermethylation associated with the epidermal growth factor receptor (EGFR) gene in animal 
models correlates with aortic valve calcification that leads to cardiac hypertrophy (Abi Khalil, 
2014). Furthermore, DNA hypomethylation in mice with atherosclerosis contrasts the 
hypermethylation of estrogen receptor alpha (ERα) and estrogen receptor beta (ERß) genes found 
in human patients with atherosclerosis (Abi Khalil, 2014). Although not fully understood, 
differential methylation status appears to be an underlying mechanism of various examples of 
CVD, yet this genetic contribution to CVD remains elusive. A better understanding of the 
epigenetic regulation of genes associated with CVD may lead to a new path of prevention and 
therapy (Ordovás & Smith, 2010). Heritable epigenetic modifications due to behavior such as 
smoking may also increase CVD risk. In children exposed to tobacco smoke while still in the 
womb, CpG islands (5’-C-phosphate-G-3’ regions in DNA) typically hypermethylated are 
observed at a significantly reduced level of methylation (Breton et al., 2009; Ordovás & Smith, 
2010). The possible connection of reduced methylation as an epigenetic adaptation to increase 
predisposition to disease later in life may provide further understanding of CVD and risk 
associated factors. Beyond CVD, DNA methylation patterns established during development, 
particularly in the hippocampus, extend well into adulthood (Brown et al., 2008). The spatial 
organization of and degrees of methylation impact physiological function and determination of 
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cell type. In this way, the prenatal methylation by DNA methyltransferases influences the 
hippocampus and development of the adult brain (van IJzendoorn et al., 2011). 
Changes in methylation and methylation machinery leading to abnormal methylation status 
of promoters and regulatory regions of gene expression underlie rare diseases of 
immunodeficiency, centromeric instability, facial anomalies syndrome (ICF), and Rhett syndrome 
(Jones & Takai, 2001). Aberrant epigenetic changes lead to other cognitive dysfunctions as well. 
Synaptic plasticity from epigenetic regulation is misregulated in cases such as Alzheimer’s disease, 
Huntington's disease, and psychiatric disorders including schizophrenia and addiction (Halušková, 
2009). Ultimately, while more thoroughly researched in some diseases compared to others, 







A disease that has plagued the world since Egyptian times and a medical undertaking since 
the early 1900s, cancer has captivated the research world for many years. The National Cancer 
Institute predicts that in 2020, approximately 1.8 million people will be diagnosed with cancer in 
the US alone, and roughly 606,520 people will die of cancer (Cancer Statistics - National Cancer 
Institute, 2015). As both a genetic and epigenetic disease, cancer studies attract a variety of 
attention, with fields of research focusing on prevention, detection, and treatment. Previous 
research in cancer epigenetics has demonstrated the power of tracing methylation status of 
candidate genes (Halušková, 2009). For example, in the bladder, methylation of the Rb1 gene has 
been investigated as a potential indicator for cancer progression and development (Halušková, 
2009; Malekzadeh et al., 2009). Additionally, in the study of biomarkers for cancer screening and 
prognostic markers, eight genes of interest have been identified in ovarian cancer (Halušková, 
2009; Su et al., 2009; Zhang et al., 2008). Hypermethylation of DNA mismatch repair genes such 
as human mutL homolog1 (hMLH1) and human mutS homolog 2 (hMSH2) in ovarian cancer were 
identified as potential prognostic markers (Zhang et al., 2008). Furthermore, methylation status of 
three genes from the secreted frizzled receptor proteins (SFRP1, SFRP 2, and SFRP 5) family, 
SRY-box 1 (SOX1), paired box gene 1 (PAX1), and LIM homeobox transcription factor 1 alpha 
(LMX1A) were investigated as markers for ovarian cancer screening and potential prognostic 
indicators (Su et al., 2009). Downregulation of the SFRP family has also been linked to aberrant 
activation of the Wnt signaling pathway which promotes tumor progression (Kawano & Kypta, 
2003). Hypermethylation of genes in the SFRP family has also been implicated in multiple cancers, 
specifically the hypermethylation of SFRP1 in hepatomas, of SFRP2 in gastric cancers, and of 
SFRP4 in colorectal cancers (Cheng et al., 2007; Feng Han et al., 2006; Shih et al., 2007).  
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With an abundance of research that continues to grow, cancer epigenetics has become a 
very specific scientific niche that has been defined as “the study of somatically heritable changes 
in molecular processes that influence the flow of information between the DNA of cancer cells 
and their gene expression patterns” (Cancer Epigenetics - Latest Research and News | Nature, 
n.d.). While this definition encompasses many fields of interest, including histone modifications 
and nuclear organization in tumor cells, this thesis focuses specifically on DNA methylation. As 
previously stated, DNA methylation is required for normal mammalian development, gene 
regulation, genomic imprinting, and chromatin structure (Bird, 2002). Using DNA methylation 
and subsequent alterations in gene expression is increasingly popular as a potential biomarker and 
risk assessor for cancer (Kerachian et al., 2020; Verma & Manne, 2006; E. M. Wong et al., 2020). 
Particular attention has been directed at analyzing the varying degrees of DNA methylations and 
identifying patterns common amongst cancer forms. DNA methylation predominantly occurs in 
three degrees of severity: hyper, hypo, and simple methylation. However, hundreds of 
methylations can occur at a time at many locations on a strand of DNA. Identifying specific 
methylation sites in cancer tissue versus normal tissues continues to be a source of screening and 
prognostic evaluators. In squamous cell lung carcinoma, significant hypermethylation in tissue 
derived from tumors versus non-tumor derived lung tissue has led to the identification of twenty-
two methylation markers, across eight different genes (Anglim et al., 2008; Halušková, 2009). 
Figure 1.3 compares the distribution and frequency of hypermethylation and hypomethylation in 






Figure 1.3 Locations of hyper and hypomethylation in colorectal cancer. Figure from 
Kerachian et al., 2020 showing a data summary schematic of the location and frequency of 
hypermethylation and hypomethylation uncovered in colorectal cancer tissue as opposed to healthy 




Nuclear Hormone Receptors 
Nuclear hormone receptors (NHRs) are a group of ligand activated transcription factors 
that can bind to both steroid hormones and lipophilic, non-steroid hormones and serve as signal 
transducing molecules in multicellular organisms (Lalli, 2014; McCabe, 2007; Vanden Heuvel, 
2015). An overview of the ligand binding NHR pathway is shown in Figure 1.4, where an 
extracellular hormone signal initiates a cascade reaction that travels through the cytoplasm and 
into the nucleus where the NHR binds to DNA promoter regions and induces a change in gene 
expression. NHRs control a broad range of processes, including the regulation of cell growth and 
proliferation, cardiovascular function, reproduction and sexual determination in development, just 






Figure 1.4 Activation of the nuclear hormone receptor (NHR) pathway. Figure adapted from 
Heskett, 2014 demonstrating the nuclear hormone pathway at a cellular level. The process begins 
inside the cytoplasm where a hormone binds to the nuclear hormone receptor complex and 
dimerizes. The dimer is actively transported into the nucleus where a coactivator attaches to the 
dimer to assist in the binding of RNA polymerase. This complex attaches to the hormone response 





The functionality of NHRs follows their unique structure consisting primarily of two major 
regions: the DNA Binding Domain (DBD) and the Ligand Binding Domain (LBD) (Figure 1.5). 
The DBD, located near the N-terminus of most NHRs, is composed of two highly conserved zinc-
finger regions that mediate binding to specific DNA sequences typically located in the promoter 
region of target genes. The DNA regions that are bound by a NHR are called hormone response 
elements, or HREs, and consist of two repeats of a hexanucleotide sequence. The LBD is located 
at the C-terminal region of NHRs and is responsible for hormone binding which, in turn, results in 
a conformational change in the NHR structure. This conformational change affects the interaction 
of various NHR cofactors, which can be classified as either coactivators or corepressors, and 





Figure 1.5 Multi-dimensional representation of a standard NHR. Figure adapted from Fruchart 
et al., 2019 providing the general structure of NHRs. The A/B, D, and F regions are variable while 
the C and E regions are conserved through all classes of NHRs. Region A/B is the variable N-
Terminal, Region C is the DNA binding domain or DBD, Region D denotes the hinge region, E is 






Based on dimerization and DNA-binding properties, NHRs fit into one of four different 
groups: steroid hormone receptors, repeat (RXR) and symmetrical repeat (LXR) binding receptors, 
ligand-dependent receptors, and monomeric receptors that bind to core sites (Table 1.1) 
(Mangelsdorf et al., 1995). All of these NHRs share certain common structures and functional 
domains, but they differ in how and where they bind to target HRE sequences based on variations 
occurring in the N-terminal region, C-terminal region, and hinge region. For instance, steroid 
receptors (Type 1) typically bind ligands in the cytoplasm before being actively transported into 
the nucleus, while RXR heterodimers (Type 2) remain in the nucleus at all times. Both steroid 
receptors (Type 1) and dimeric orphan receptors (Type 3) bind HREs with sequence specific 
binding recognition half-sites, but Type 1 binds to inverted HREs that are separated by a variable 
region, and Type 3 binds to HREs that are direct repeats. Unlike Types 1, 2, and 3, Type 4 NHRs 
bind to only a single half-site HRE on the target gene (Klinge, 1997). Most orphan nuclear 




Table 1.1 The four subclasses of nuclear hormone receptors. Adapted from Mangelsdorf et al., 
1995, each class of NHR is identified by the variable region based on dimerization and DNA-
binding properties. The regions labeled with question marks represent orphan segments where the 
ligands remain unknown.  
 Dimerization HRE Binding Examples 













separated by a 
variable region 
Thyroid Hormone Receptor, 
Eicosanoid Receptor 
Type 3: Dimeric 
Orphan Receptors 
Homodimer Direct repeat half-
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Critically, nuclear hormone receptors play complex roles in cancer progression and 
tumorigenesis. One such example of the complexity of NHRs in cancer is the repression of thyroid 
hormone nuclear receptors (TRs) that mediate the growth, differentiation, and metabolic functions 
that are promoted by thyroid hormone. Studied in breast and colon cancer, TR is expressed in low 
quantities and due to crosstalk with the tumor suppressor protein p53, TR cannot function as a 
gene activator and regulator of cancer cell growth (Bhat et al., 1997). Other studies have 
highlighted the importance of NHRs as drug targets for cancer treatment. Specifically, the 
expression of orphan nuclear hormone receptors in the subfamily NR4A1/NUr77/NGFIB have 
been implicated in the progression of cervical cancer. Research suggests that these NHRs are 
affiliated with the survival of cervical cancer cells and that the downregulation of gene expression 
of NR4A2 may suppress cancer progression (Ke et al., 2004). Alternatively, the NR4A nuclear 
receptor family serves as tumor suppressors in Acute Myeloid Leukemia (AML) where oncogenic 
promoting pathways are aberrantly activated and overexpressed (Call et al., 2020). Other tumor 
suppressors such as the Nuclear Receptor Subfamily 0, Group B Member 2 (NR0B2), also referred 
to as the small heterodimer partner, SHP, are epigenetically silenced via hypermethylation in the 
promoter region in hepatocellular carcinoma (He et al., 2008). Thus, expression of nuclear 
receptors have increasingly become possible therapeutic targets for cancer treatment (Call et al., 
2020). This further gives rise to the possibility that expression of the gene of interest for this thesis, 






The gene and nuclear hormone receptor DAX-1, is the focus of the experiments outlined 
in this thesis. As previously described, most nuclear receptors bind directly to HRE sequences in 
the promoter regions of target genes. However, orphan nuclear receptors, including DAX-1, lack 
a ligand binding domain (LBD) yet can still mediate functions such as dimerization and coactivator 
interactions. DAX-1 specifically belongs to the subfamily of orphan hormone nuclear receptors. It 
is identified as an orphan because, unlike the steroid and non-steroid hormone receptors, DAX-1 
has not been shown to bind to a specific ligand. As its name implies, multiple copies of the DAX-
1 gene region on the X chromosome are associated with male to female sex reversal in human 
development (Dosage Sensitive Sex Reversal, or DSS). The role of DAX-1 in this context is as a 
negative regulator of estrogen, progesterone, and androgen receptors and therefore, antagonizes 
testicular development through inhibition of gene expression (Iyer & McCabe, 2004). More 
generally, DAX-1 is characterized as a repressor of gene expression activated by ligand-induced 
transcriptional activation (Lalli, 2014; Lalli et al., 1997). DAX-1 suppresses steroidogenesis in 
adrenal cells by binding to hairpin DNA structures. However, the function of DAX-1 goes beyond 
suppression; the unique structure of this NHR allows for transcriptional silencing. DAX-1 serves 
as a form of tumor assessor in prostate cancer and pituitary adenomas as well as an indirect tool 
for measuring androgen receptor expression in breast cancer and estrogen receptor expression in 






As an orphan receptor, DAX-1 does not follow the typical NHR structure. Instead, DAX-
1 lacks the modulator and hinge regions as well as the conserved zinc finger DNA binding domain 
(Figure 1.6). Intriguingly, DAX-1 has three times as many leucine rich LXXLL repeats than are 
commonly found in coactivator proteins that are important in mediating binding to ligand induced, 
AF-2 (Activating Function 2) domains on other NHRs (Lalli, 2014; Zanaria et al., 1994). The 
complex formed by the LXXLL motif and the LBD can then recruit the silencing domain in the 






Figure 1.6 Structure of the DAX-1 NHR compared to a typical NHR. Unlike other nuclear 
receptors, DAX-1 does not have a modulator (A/B) or hinge region (D) and what would be the 
DNA binding domain (DBD, region C) is missing the zinc finger region that is typical in other 
nuclear hormone receptors. Instead, the DAX-1 DBD contains three leucine rich LXXLL repeats 
that have been shown to mediate cofactor binding in other nuclear hormone receptors. The DAX-
1 protein consists of 470 total amino acids, with the N-terminal region spanning the first 253 amino 
acids. The DBD is located in this region and includes 3 complete and one incomplete 






Orphan NHR’s can regulate gene expression and endocrine responses without binding to a 
ligand. This process is referred to as the ligand independent pathway (Figure 1.7). In the absence 
of a ligand, nuclear receptors work in conjunction with coregulators through protein-protein 






Figure 1.7 Ligand independent binding nuclear hormone receptor pathway. Figure adapted 
from Guo & Ren, 2013, highlights the mechanism of NHRs within the nucleus. In the absence of 
a ligand, the NHR binds a corepressor that leads to transcriptional repression. Upon ligand binding, 






Coregulators are classified as either coactivators or corepressors. Coactivators bind to the 
ligand-dependent (or ligand activated) NHRs to increase target gene expression. Figure 1.8 shows 
the activated Liver X Receptor (LXR) bound by a ligand which will form a heterodimer with 
Retinoid X Receptor (RXR). Together, they are bound by a coactivator that recognizes target genes 
(Zanaria et al., 1994). Conversely, corepressors bind to unliganded NHRs, resulting in a decrease 






Figure 1.8 Mechanism of a Type 2 NHR binding with coactivator. Figure adapted from 
Heskett, 2014; only one nuclear receptor of this heterodimer can bind a ligand, in the example 






Thus, while the ligand binding domain (LBD) of an orphan NHR such as DAX-1 does not 
bind to any specific ligand, it does have other functions. Namely, the LBD is important for receptor 
dimerization and coactivator interactions. There are three pathways (Figure 1.9) that describe the 
mechanisms by which DAX-1 can repress transcription during gene regulation: by binding the AF-
2 site of another NHR, by hijacking the coactivator binding domain in other NHRs, or by binding 





Figure 1.9 The three ways in which DAX-1 can repress transcription. Adapted from Iyer & 
McCabe, 2004, DAX-1 can silence gene expression via three pathways. A) DAX-1 hijacks an 
activator (AR) and prevents it from entering into the nucleus. B) DAX-1 inhibits gene expression 
by binding the AF-2 site of another NHR and works in conjunction with corepressors. C) DAX-1 





Previous research has shown that NHRs regulate a wide-range of normal biological 
processes, including embryonic development and sex determination (Lalli, 2014). In embryonic 
stem cells, orphan NHRs, specifically LRH-1, DAX-1, and SF-1, work together with a complex 
of proteins to maintain pluripotency. DAX-1, in particular, functions to maintain totipotency in 
embryonic stem cells and was first associated with X-linked adrenal hypoplasia congenita (AHC) 
and dosage sensitive sex reversal (DSS) in these cells (Lalli et al., 1997; McCabe, 2007). In DSS, 
mutations on the X chromosome result in sex reversal due to a duplication in the region containing 
the DAX-1 gene (Lalli, 2014). When expressed in the hypothalamus and pituitary, mutations in 
DAX-1 are responsible for most cases of cytomegalic AHC and may also cause hypogonadotropic 
hypogonadism (HHG) (McCabe, 2007). AHC specifically is the result of mutations in the DAX-1 
gene that cause diminished development of adrenal tissue, leading to a reduction in adrenal 
hormone production (Lalli et al., 1997). Since this initial discovery of DAX-1 function, DAX-1 
has quickly become a topic of scientific interest because of its presence in all regions of the 
hypothalamic-pituitary-adrenal-gonadal (HPAG) axis during development and in adult tissues.  
NHRs have been shown to play important roles in abnormal physiological processes, 
including tumor cell initiation and cancer progression. Previous studies by our lab and others have 
shown DAX-1 is expressed in different breast and prostate cancer cell lines, however, expression 
levels vary widely (Boitano, 2009; Heskett, 2014). Our lab has found that DAX-1 functions, in 
general, as a repressor of cancer cell growth. While the potential correlative effects of DAX-1 and 
cancer have been studied in breast, prostate, lung, adrenal, and liver cancer, the precise mechanism 
of this action is not well understood. In order to better understand the role of DAX-1 not only in 
regulating cancer cell growth, but also in normal physiological functions, it is essential to 
determine what factors are directly responsible for controlling its expression (Conde et al., 2004; 
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He et al., 2008; Heskett, 2014; Jiang et al., 2014; Kudryavtseva et al., 2018; Kumata et al., 2018). 
We hypothesize that the DAX-1 gene is epigenetically regulated, specifically via methylation, 
in cancer cells, thereby reducing its expression. Differences in the methylation of CpG islands 
located near the DAX-1 promoter result in the variation of DAX-1 expression in different 
human cell lines. To investigate this hypothesis, a broad assessment of the promoter region of the 
DAX-1 gene was initially performed. Initial experiments explored DAX-1 expression at the RNA 
and protein levels. These results were then followed by assays broadly identifying degrees of 
methylation of CpG islands. Most DNA methylation occurs at CpG islands where there is a high 
concentration of CpG dinucleotides and can suppress the expression of nearby genes 
(Manoochehri et al., 2016). Within the promoter region of the human DAX-1 gene, there are nine 




Figure 1.10 Promoter region of Exon 1 of the DAX-1 gene. Highlighted in red is the 
transcriptional start site. Each region highlighted in yellow is a CCGG CpG island that may be a 





Following this initial analysis, the focus of this project was refined to investigate three cell 
lines: one cancerous cell line with a high degree of methylation, one cancerous cell line with a low 
degree of methylation, and one non-cancerous control cell line. Within these three cell lines, 
sequence analysis of bisulfite modified gDNA was utilized to more accurately assess the degree 
of methylation in a region of interest. Finally, the mechanism of DNA methylation in these cell 
lines through the use of chromatin immunoprecipitation (ChIP) assays was investigated in order 
to hone in on the different methylating protein occupancy between cancerous and non-cancerous 
breast cells. Through the following experiments, a better understanding of the factors that control 
DAX-1 expression in a variety of human cell lines was obtained. The contribution of these results 
will provide a deeper understanding as to how DAX-1 expression may be controlled in human 




Chapter 2: Determination of the level of DAX-1 expression across different 
human cell lines 
Introduction 
Previous research in the Tzagarakis-Foster lab has shown that the DAX-1 promoter region 
and exon 1 contain CpG islands that can be methylated (Dishington, 2017; Heskett, 2014; Judge, 
2011). These earlier experiments examined only a few cell lines for DAX-1 expression and 
methylation status. Thus, the first specific aim of this thesis research was to determine the level of 
DAX-1 expression across cancerous and noncancerous human cells using various molecular 
techniques including polymerase chain reaction (PCR), quantitative PCR (qPCR), western blot, 
and restriction digestion analysis.  
Each of the cell lines examined were selected for their association with DAX-1 or other 
nuclear hormone receptors based on previous research in the Tzagarakis-Foster lab or literature 
reviews (Conde et al., 2004; He et al., 2008; Heskett, 2014; Jiang et al., 2014; Kudryavtseva et al., 
2018; Kumata et al., 2018). Amongst the cell lines not previously investigated by the Tzagarakis-
Foster lab but included in this research are those derived from cervical and hepatocellular cancer. 
In 2018, cervical cancer was the fourth most lethal form of cancer in women worldwide. Studies 
have found that the DAX-1 protein is upregulated in cervical cancer and when silenced, 
tumorigenicity is inhibited (Liu et al., 2018). Furthermore, DAX-1 has been shown to 
transcriptionally repress genes that regulate oncogenic gene expression downstream. Most of the 
cell lines included in this study (e.g. testes, ovaries and breast) are associated with sex steroid 
synthesis. The exception to this is the Hep-3B cell line, which is isolated from a hepatocellular 
carcinoma. Previous findings immunolocalized synthesized sex steroids and hormone receptors, 
including DAX-1, in the mucous epithelial cells of neoplasms on the liver (Kumata et al., 2018). 
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Examination of DAX-1 expression in liver cells was included in this study to provide a comparison 
against the steroid hormone producing tissues previously investigated in the Tzagarakis-Foster 
lab.  
Ultimately, experiments confirmed the detection of DAX-1 in the genome of the cancerous 
and control cell lines. Following successful detection of DAX-1 at the genome level, RNA and 
protein level analyses confirmed differential expression of DAX-1 within the cancer cell lines. 
General analysis of methylation status was assessed with methylation specific restriction enzyme 
assays. The restriction enzyme analysis highlighted the diverse levels of methylation across the 







Materials and Methods 
Tissue Culture 
Cell lines, obtained from American Type Culture Collection, were cultured according to 
the recommended guidelines (ATCC Cell Lines, n.d.). Antimycotic and antibiotics were added to 
the media to prevent bacterial and fungal infection of the lines. Multiple cancer cells lines were 
analyzed for the differential expression and varying degrees of hypermethylation of the DAX-1 
gene. The MCF10A cell line is derived from an immortalized breast tissue and serves as a non-
cancerous control. While MCF10A cells are non-cancerous and not derived from a tumor, they are 
not considered ‘normal’. The MCF10A cells originate from a tissue sample of a patient with 
fibrocystic disease and were immortalized through consistent passaging of the cells in a low 
calcium media. In addition to this control cell line, five cancerous cell lines (Table 2.1) were 
analyzed for DAX-1 expression. Each cell line was chosen based on prior investigation by the 
Tzagarakis-Foster lab or the association that each particular cancer has with nuclear hormone 
receptors such as DAX-1. Previous work in the Tzagarakis-Foster lab has shown that DAX-1 is 
expressed in varying degrees within breast, lung, and adrenal cancer cell lines. In addition to these 
cell lines, cervical adenocarcinoma cells and liver cells, shown to express DAX-1, were also 
assessed (Kumata et al., 2018; Liu et al., 2018). MCF7 cells are human epithelial cells from a 
female with breast cancer (adenocarcinoma) and express estrogen receptors alpha and beta and are 
responsive to estrogen hormones. Human lung cancer cells, A549 cells, were taken from an adult 
male with carcinoma. SW13 cells are derived from a female with grade IV carcinoma in the adrenal 





Table 2.1 Cell lines used to investigate DAX-1 expression. 
MCF7 Metastatic (pleural effusion) mammary gland, breast cancer 
A549 Lung, Carcinoma 
HeLa Cervical adenocarcinoma 
SW13 Carcinoma, adrenal gland/cortex 
Hep-3B Liver, hepatocellular carcinoma 






Standard polymerase chain reaction (PCR) was performed to confirm the presence of DAX-
1 in each cell line. Genomic DNA (gDNA) was isolated from cultures grown in T75 tissue culture 
flasks using the PureLink® Genomic DNA Mini Kit (Invitrogen, Life Technologies, catalog # 
K1820-02). Following gDNA isolation, samples were quantified using a Nanodrop 
spectrophotometer and each sample was normalized to 150ng per μL. Genomic DNA samples 
were analyzed for DAX-1 genomic detection using PCR. Samples were prepared using GoTaq 2x 
Master Mix (Promega), and primers were designed to two different regions of the X chromosome 
region containing the DAX-1 gene region. The first primer set amplified a region spanning from 
Exon 1 into Intron 1, and the second targeted a region entirely within the first intron. Targeting 
these regions ensured that amplified products were generated from genomic DNA as opposed to 
mRNA. PCR conditions and primers (Tables A.1 and A.2; Appendix A) obtained from Integrated 






In order to assess DAX-1 mRNA expression in the cell lines, quantitative PCR, or qPCR, 
was utilized. qPCR, as opposed to “end-point” PCR, combines the amplification and detection 
steps and allows for quick and highly accurate data collection. Furthermore, the process is highly 
sensitive compared to alternative methods, and can detect differential gene expression more 
precisely between samples with lower degrees of variation (M. L. Wong & Medrano, 2005). 
Confluent cells were isolated from T75 tissue culture flasks and total RNA was isolated using the 
Monarch® Total RNA Miniprep Kit from New England Biolabs® Inc. (Product # T2010S). 
Following RNA isolation and quantification using a Nanodrop spectrophotometer, cDNA was 
synthesized using Maxima H Minus First Strand cDNA Synthesis Kit (Thermo Fisher, Product # 
K1651). qPCR reactions were prepared using PerfeCTa® SYBR® Green Fast Mix® from 
QuantaBio (Cat. # 95072-250, -012, -05K). SYBR green exhibits very little fluorescence when it 
is free in solution, but the fluorescent signal increases substantially when it binds non-specifically 
to double stranded DNA. cDNA samples were amplified using primers directed to the DAX-1 gene. 
Primer and qPCR parameters (Tables A.1 and A.2; Appendix A) were used to isolate a region of 
the DAX-1 gene that was not removed during RNA splicing.  
The first means of assessing DAX-1 RNA expression utilized the standard curve method 
(Qiagen, n.d.). In this approach, a set of serial dilutions was prepared from a DNA template of 
known concentration. These samples were used to obtain a standard curve that was used for the 
relative quantification of unknown samples. The DNA template used to prepare a standard curve 
was generated from the same DAX-1 amplicon that was generated using a DAX-1 plasmid. The 
amplified DAX-1 plasmid DNA was prepared with the Wizard® SV Gel and PCR Clean-Up 
System (Product # A9281, Promega). Amplification and analysis was performed using the BioRad 
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CFX-96 system. Utilizing this plasmid as a control allowed for direct quantitative comparison of 
DAX-1 expression in the experimental cell lines. Data was collected in sets of three technical 
replicates per biological sample and over a minimum of three biological replicates. The standard 
deviation corresponds with the triplicate samples analyzed on a single 96-well plate and was 
calculated in Microsoft Excel with the following equation (Microsoft, n.d.): 
!"#$%#&%	()*+#"+,$ = !.(/0 = 	1∑(#!$#"#$)%(&$')  ; Where xi is a single value, xave is the mean of 
the sample set, and n is the number of samples. 
 
In addition to utilizing a standard curve of DAX-1 plasmid for comparison described 
above, a second means of analysis was also implemented. In this approach, each of the cancerous 
cell lines was normalized against the control cell line to compare relative DAX-1 expression in 
cancerous versus noncancerous cells. The normalization was calculated based on the Cq value (the 
number of amplification cycles) with the following equation:  
2$∆)&, where ∆4* =	4*	,-./01 −	4*	23&4530 	, or ∆4* =	4*	2-&21536, −	4*	7)8'9: 
 
The following equation was used to calculate the standard error of the two means from the 
normalized cell lines against the noncancerous MCF10A cells (Comparison of Means Calculator, 
2021): 
!"#$%#&%	/&&,& = 1(&'$'),'%	;	(&%$'),%%(&';	&%)$<  ; where n1 is a single Cq sample, n2 is a single Cq MCF10A, 
s1 is the standard deviation between the sample replicates, s2 is the standard deviation between 




Protein Isolation and Western Blot Analysis 
Total protein lysate from confluent 10 cm tissue culture dishes was collected using the Cell 
Extraction Buffer kit (Invitrogen, Life Technologies, Ref# FNN0011) and Halt™ Protease 
Inhibitor Single-Use Cocktail (1000X) from Thermo Scientific (Ref #1860932). Protein lysates 
were quantified using a Bradford protein assay. Pre-Diluted Protein Assay Standards: Bovine 
Albumin (BSA) set from Thermo Scientific (Prod. #23208) were used to generate a standard curve, 
and samples and standards were prepared using the Bio-Rad Protein Assay Dye Reagent 
Concentrate (5x) from Bio Rad (Cat. #5000006). All samples were measured via spectroscopy. 
Western blot analysis was carried out according to the NuPAGE Novex Bis-Tris protocol 
(Invitrogen, Carlsbad, CA). 10µg of each isolated protein sample was added to NuPAGE LDS 
sample loading buffer (1X final concentration), NuPAGE reducing agent (1X final concentration) 
and nuclease free water to a total volume of 20μl. 5µL of a 10-20% Tris-glycine Gel Ladder from 
Protein Tech was loaded into one lane for sample analysis after imaging. Samples were 
electrophoresed using the XCell II Blot Module (Invitrogen, Carlsbad, CA) at 200V for 60 
minutes. Proteins were transferred to PVDF membranes using the XCell II Blot Module apparatus. 
Following transfer, PVDF membranes were washed three times in 1X TBST for 10 minutes per 
wash at room temperature. Membranes were blocked in 5% milk in 1X TBST for 1 hour at room 
temperature. Primary antibodies (DAX-1: Invitrogen anti-rabbit, GAPDH: GeneTex anti-mouse) 
were diluted 1:1000 in 5% milk in 1X TBST, and added to blots to incubate overnight on a rotator 
at 4˚C. This antibody was selected following a survey of anti-DAX-1 antibodies (Figure 2.1). 
Following overnight incubation, blots were washed three times for ten minutes in 1X TBST and 
incubated for 60 minutes at room temperature in secondary antibody diluted 1:2000 (GeneTex 
anti-rabbit, BD Pharmingen anti-mouse) in 5% milk in 1X TBST. PVDF membranes were washed 
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three times for 10 minutes in 1X TBST. In order to detect protein-antibody complexes, 
chemiluminescent SuperSignal™ West Femto Maximum Sensitivity Substrate (Thermo Scientific 
REF 34095) was added to each membrane and incubated according to the manufacturer’s 
recommendation. Membranes were exposed and images captured using the GelDoc Imager and 





Figure 2.1 Optimization of primary antibody selection for assessing DAX-1 protein 
expression. While faint ‘on-target’ bands are visible at 50kDa indicating antibody binding the 
DAX-1 in lanes 1-4, maximum signal was detected with the primary anti-DAX-1 antibody for 





Methylation Specific Restriction Enzyme Analysis and PCR  
For each cell line, genomic DNA was isolated and used for methylation specific restriction 
enzyme digestion and analysis. Genomic DNA (gDNA) was isolated through the same technique 
described previously. The gDNA samples were digested using methylation-sensitive restriction 
enzyme HpaII and its isoschizomer MspI, which has the same recognition site but is methylation 
insensitive (New England BioLabs, Inc.). A fragment was designated ‘unmethylated’ if no PCR 
product was observed after digestion; alternatively, the fragment was designated ‘methylated’ if it 
was amplified after digestion (Melnikov, 2005; Salmon et al., 2008; Yang et al., 2011). Together, 






Figure 2.2 Methylation status sensitivity to enzymes HpaII and MspI. Figure adapted from Fu 
et al., 2012, these enzymes target CCGG CpG islands and ‘cut’ depending on the location of the 
methyl group. These enzymes have a sensitivity to CCGG methylation status and can determine 
the location of methylation through a restriction digest of the gDNA when primed to target the 
promoter region of DAX-1. The addition of a methyl group (CH3) protects against enzyme 
digestion. Therefore, regions marked as ‘cut’ are unprotected and regions marked as ‘not cut’ are 




Both of these enzymes target CpG islands, specifically those of CCGG sequence. Reactions 
containing enzyme, specific buffer, and gDNA were incubated at 37˚C for 2 hours. This method, 
while limited in that it is only a very crude examination of methylation status, can be used to 
quickly assess the methylation status of the DAX-1 genomic region in the cell lines described 
previously. When compared alongside control gDNA, the intensity of products was used to 
determine whether a CpG-rich region was either hemi-methylated or methylated, unmethylated, 
or fully methylated. Both the gel image product and the corresponding band intensity were used 
to categorize CpG islands into one of these three degrees of methylation. A region and its 
respective CpG island(s) were marked as hemi-methylated or methylated if the product in the 
HpaII lane was of similar intensity as the undigested control, or if the HpaII and MspI lanes both 
showed relatively similar products to each other and the control. Alternatively, a region of CpG 
island(s) was considered methylated following MSRE if the product of the HpaII digest was more 
intense than the control or if it was less than the control and there was negligible product following 
digestion by MspI. Finally, a region and the associated CpG island(s) was deemed unmethylated 
if there was little to no PCR amplified product following both HpaII and MspI digestion. 
Following the restriction digest with HpaII or MspI enzymes, DNA was purified (Monarch 
PCR DNA cleanup kit, New England Biolabs, Inc.) and used as template for standard PCR 
reactions. CpG islands targeted by HpaII/MspI enzymes were located on the NR0B1/DAX-1 
sequence using the Li Lab MethPrimer software (L. C. Li & Dahiya, 2002). This software 




Figure 2.3 CpG rich regions of the DAX-1 promoter. CpG rich regions were identified and 
compiled using the Meth Primer tool for the Li Lab (L. C. Li & Dahiya, 2002). The transcriptional 





Having identified CpG-rich regions, primers for the PCR reactions were designed using 
Primer3 software v0.4.0 (Kõressaar et al., 2018; Koressaar & Remm, 2007; Untergasser et al., 
2012), so that primers would flank the HpaII/MspI enzyme cutting site (5′-CCGG-3′) in the 
sequences. Particular attention was given to designing these primers, breaking the CpG-rich region 
of the DAX-1 promoter into five sub-regions that each contained at least one CCGG sequence 
(Figure 2.3). Furthermore, the primers were developed such that melting temperatures were 
relatively similar with 5-10˚C difference between primer sets (Table A.2; Appendix A). In an 
effort to use these primers in tandem with the digested gDNA, some of the amplified regions 
overlap and encompass the same CpG islands (Figure 2.4). Region A isolated one CpG island and 
Region B encompassed three unique CpG islands. Regions C and D overlapped, each including 1 
unique CpG island, and Region E targeted one CpG island. While MSRE provided a crude 
assessment of methylation status, minimizing the number of CpG islands targeted within each PCR 







Figure 2.4 The DNA sequence of DAX-1 promoter region with MSRE primers. Five different 
primer sets are shown, each amplifying a different CpG island. Forward and reverse primers are 
highlighted along with the CpG islands the amplified region encompasses. Primer design Region 
A is yellow, Region B is blue, Region C is purple and overlaps with Region D in pink, Region E 
is in green.  
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All PCR reactions were performed using Promega GoTaq Green Master Mix (catalog # 
M7121) (Table A.1; Appendix A). Endpoint PCR products were separated by electrophoresis 
through a 2% agarose gel with ethidium bromide and visualized using the BioRad Gel Doc Imager. 
Only products that had not been digested by the enzyme could be amplified via PCR, resulting in 
a product visible on the agarose gel. Quantitative values were derived from band intensity via 
densitometry using the ImageLab software associated with the gel doc (Image Lab Software | Life 





gDNA DAX-1 Detection 
The initial confirmational assay was crucial to determining that DAX-1 is present within 
the cancerous and immortalized cell lines. Cancer frequently involves mutagenesis, often resulting 
in chromosomal aberrations (Chinnaiyan & Palanisamy, 2010). Since the DAX-1 gene is found on 
the X chromosome, determining that a potential chromosomal aberration had not disrupted this 
target gene was critical prior to assessing RNA and protein level expression of DAX-1. To check 
this, DAX-1 genomic level detection was assessed with standard PCR and the products were 
visualized using gel electrophoresis. As shown in Figure 2.5, PCR products of the appropriate size 
in all cell lines assayed, confirm the DAX-1 gene is intact and mutation in these cell lines has not 






Figure 2.5 Detection of DAX-1 in the genome. Amplification of two distinct regions of the 
genome containing the DAX-1 gene followed by gel electrophoresis is shown. Six different cell 
lines were analyzed: MCF10A non-cancerous immortalized breast cells, A549 lung carcinoma, 
HeLa cervical cancer, Hep-3B liver carcinoma, MCF7 breast cancer, and SW13 adrenal cancer. 





DAX-1 RNA Level Expression 
Quantitative PCR (qPCR) was utilized to measure the level of DAX-1 gene expression in 
each cell line. For these experiments, two quantification methods were employed. In the first 
approach, a standard curve was generated using known input amounts generated from PCR 
amplification using a DAX-1 expressing plasmid as the DNA template. In the standard curve 
method, a range of known concentrations of DAX-1 plasmid were used to derive quantitative 
comparisons of RNA level expression. Beginning at 1ng/µL and decreasing to a low concentration 
of 0.1pg/µL, the number of amplification cycles needed to detect DAX-1 in the plasmid increases 
as concentration decreases. By comparing the resulting Cq value (the number of amplification 
cycles) derived from the standard curve to the Cq values of the experimental samples, relative 
levels of DAX-1 expression in the cancerous and noncancerous cell lines was determined (Figure 
2.6). In this quantification method, the higher Cq value indicates an increased amount of qPCR 
cycles required to detect DAX-1. Thus, the larger the Cq, the lower the level of DAX-1 expression. 
Based on this method of mRNA expression analysis, the highest level of DAX-1 expression is 
observed in the A549 lung carcinoma cell line. This high level of expression is followed closely 
by the SW13 adrenal carcinoma cancer cell line. In contrast, it took much longer for the qPCR to 
detect DAX-1 RNA expression in the MCF7 breast cancer cell lines. Alternatively, DAX-1 
expression in HeLa and Hep-3B (cervical and hepatocellular carcinoma), was between 1pg/µL and 
0.1pg/µL, slightly higher than that detected in the MCF7 cell line. The DAX-1 RNA expression in 
the MCF10A control cell line was also relatively low. This was to be expected as breast cells are 
not major producers of DAX-1 such as adrenal cells that require DAX-1 to regulate steroid 





Figure 2.6 Quantitative assessment of the DAX-1 RNA level expression compared to a 
standard curve developed from the DAX-1 plasmid at varying concentrations. The standard 
curve generated from the DAX-1 plasmid superimposed over the average Cq levels of each tested 























In a more qualitative approach comparing relative DAX-1 expression levels in the 
cancerous cell lines to the control, the differences in expression is striking (Figure 2.7). When 
compared to the MCF10A non-cancerous control cell line, it is evident that the A549 lung 
carcinoma and SW13 adrenal carcinoma have substantially higher levels of DAX-1 expression 
than the Hep-3B hepatocellular carcinoma, the HeLa cervical carcinoma, or the MCF7 breast 







Figure 2.7 Fold ‘Relative’ Expression of DAX-1. Each cancerous cell line was normalized 
against the control, non-cancerous cell line for relative DAX-1 RNA level expression. A549 and 






DAX-1 Protein Level Expression 
Western Blot analysis, that was used to determine the qualitative level of DAX-1 gene 
expression at the protein level paralleled what was observed at the mRNA level. Protein expression 
was compared to that of GAPDH, a housekeeping gene that is constitutively expressed in all cells 
but may vary slightly amongst different cell types. Expression levels were based on the intensity 
of the product band during chemiluminescent imaging. Similar to the RNA level experiments, the 
western blot results confirm differential expression of DAX-1 across the cell lines (Figure 2.8). In 
line with what was observed at the RNA level, lung (A549) and adrenal (SW13) carcinomas 
demonstrated the highest DAX-1 protein expression while the breast cancer cell line (MCF7) had 
low expression. The hepatocellular carcinoma (Hep-3B) cells gave protein expression results 
consistent with those obtained from the RNA level analyses, categorizing them as low expressors 
of DAX-1 in both experiments but having slightly higher expression than that of the MCF7 cell 
line. However, some variation is observed when analyzing the qualitative results of the western 
blot compared to what was observed through qPCR. While the MCF10A control cells were average 
expressors of DAX-1 mRNA, a protein product is not detected in the western blot. This could 
indicate a translational mutation in which the DAX-1 RNA is not fully converted to protein or some 
other mechanism of translational control that does not align with transcriptional control in this cell 
line. In contrast, the cervical carcinoma (HeLa) cells are high expressors of DAX-1 at the protein 





Figure 2.8 DAX-1 protein expression assessed via western blot. The control cell line is labeled 








Having observed differential DAX-1 expression at both the RNA and protein levels, 
methylation specific restriction enzyme analysis provided a means to investigate the potential 
correlation between methylation and expression. Using the isoschizomer enzyme pair HpaII and 
MspI, the methylation status of the nine CCGG CpG islands in the DAX-1 promoter was crudely 
assessed. A product should always be observed in the control, undigested sample. The gDNA 
treated with HpaII enzyme will cut differentially based on the location and degree of methylation. 
Finally, while the MspI enzyme should cut regardless of methylation status and therefore 
theoretically never show a band, there are instances in which not all the gDNA was cut or it was 
cut in a way that the primers could still anneal, resulting in some product amplification.  
Beginning with Region A, containing one CCGG CpG island, there was considerable 
variation in methylation status across the six cell lines (Figure 2.9). Based on the gel product 
shown above the bar graph and the quantitative values indicated by the blue bars, the MCF10A 
control cells are either methylated or hemi-methylated at this CpG island. In this case, the 
categorization of either hemi-methylated or methylated results from a greater band intensity 
following HpaII digestion, as well as some product following MspI digestion. Furthermore, both 
digest products are comparable to the results of the control. Denoted in orange, the cancerous cell 
lines can be assessed both qualitatively with the gel images or quantitatively with band intensity. 
The DAX-1 gene in SW13 adrenal gland carcinoma, Hep-3B hepatocellular carcinoma, and MCF7 
breast cancer cells are all hemi-methylated or methylated at this CpG island. This was determined 
based on the relative intensity of bands following PCR amplification. The Hep-3B cells showed 
some product following both digests, with the band intensity following HpaII digestion being 
comparable to that of the control. Products from both digests are observed in the MCF7 cells as 
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well, however with the SW13 cells it is more difficult to group this region into hemi-methylation 
or methylation because of the intensity of the control when compared to either digest product. In 
clear contrast however, the A549 lung carcinoma cells appear to be almost certainly unmethylated 







Figure 2.9 Methylation status of DAX-1 Region A as assayed by MSRE. Based on the PCR 
product following HpaII and MspI digestion, the following crude assessments can be made of this 
single CCGG CpG island: methylated or hemi-methylated in the control MCF10A cells; 
unmethylated in the A549 lung carcinoma cells; methylated or hemi-methylated in the Hep-3B 
hepatocellular carcinoma cells; unmethylated in the HeLa cervical adenocarcinoma cells; 
methylated or hemi-methylated in the MCF7 breast cancer cells; and methylated or hemi-




The restriction digest results from the SW13 cell line in Region A highlight one of the 
reasons why MSRE can only be used to crudely assess methylation status. Analysis of Region B 
provides another example of why this technique is generally useful to begin honing in on areas of 
interest in the DAX-1 gene, but cannot be used for a precise determination of methylation status. 
This region, following the transcriptional start site and TATA box, contains three CCGG CpG 
islands that may all be methylated differently and the MSRE analysis can only indicate an overall 
methylation status and cannot distinguish each CCGG CpG island independently (Figure 2.10). 
The MCF10A noncancerous cells are either methylated or hemi-methylated in this region, as are 
the MCF7 breast cancer cells. The Hep-3B hepatocellular cells are likely methylated, and the 






Figure 2.10 Methylation status of DAX-1 Region B as assayed by MSRE. Based on the PCR 
product following HpaII and MspI digestion, the following crude assessments can be made of this 
region that encompasses three CCGG CpG islands: methylated or hemi-methylated in the control 
MCF10A cells; unmethylated in the A549 lung carcinoma cells; methylated in the Hep-3B 
hepatocellular carcinoma cells; unmethylated in the HeLa cervical adenocarcinoma cells; 
methylated or hemi-methylated in the MCF7 breast cancer cells; and unmethylated in the SW13 




Moving downstream, Region C contains one unique CCGG CpG island and two that are 
also amplified in Region D. After analyzing the Region C patterns and comparing them to Regions 
A and B, a trend amongst the cell lines emerges (Figure 2.11). Once again, the MCF10A 
noncancerous cell line is methylated at this region of the DAX-1 promoter, as are the Hep-3B 
hepatocellular carcinoma cells and the MCF7 breast cancer cells. In comparison, the lack of any 
bands, even faint, in the A549 lung carcinoma, HeLa cervical adenocarcinoma, and SW13 adrenal 






Figure 2.11 Methylation status of DAX-1 Region C as assayed by MSRE. Based on the PCR 
product following HpaII and MspI digestion, the following crude assessments can be made of this 
single unique CCGG CpG island: methylated in the control MCF10A cells; unmethylated in the 
A549 lung carcinoma cells; methylated in the Hep-3B hepatocellular carcinoma cells; 
unmethylated in the HeLa cervical adenocarcinoma cells; methylated in the MCF7 breast cancer 




Methylation status of Region D continues to support the pattern that the six cell lines fall 
into two categories: differential methylation across the DAX-1 promoter and little to no 
methylation in the DAX-1 promoter. Within Region D, containing one unique CCGG CpG island 
and two shared with Region C, the noncancerous cells, hepatocellular carcinoma cells, and breast 






Figure 2.12 Methylation status of DAX-1 Region D as assayed by MSRE. Based on the PCR 
product following HpaII and MspI digestion, the following crude assessments can be made of this 
single unique CCGG CpG island: methylated in the control MCF10A cells; unmethylated in the 
A549 lung carcinoma cells; methylated in the Hep-3B hepatocellular carcinoma cells; 
unmethylated in the HeLa cervical adenocarcinoma cells; methylated in the MCF7 breast cancer 




Finally, when analyzing Region E, which contains one CCGG CpG island, the pattern of 
differential methylation across the DAX-1 promoter or little to no methylation in the DAX-1 
promoter amongst the cell lines is further substantiated (Figure 2.13). The intense bands from the 
HpaII digest in the MCF10A, Hep-3B, and MCF7 cell lines indicated that all are likely methylated 
at this CpG island. In contrast, the lack of a product indicates that the HpaII and MspI enzymes 
were able to digest the gDNA. Therefore, the CpG island in Region E in the A549, HeLa, and 




Figure 2.13 Methylation status of DAX-1 Region E as assayed by MSRE. Based on the PCR 
product following HpaII and MspI digestion, the following crude assessments can be made of this 
single unique CCGG CpG island: methylated or hemi-methylated in the control MCF10A cells; 
unmethylated in the A549 lung carcinoma cells; methylated in the Hep-3B hepatocellular 
carcinoma cells; unmethylated in the HeLa cervical adenocarcinoma cells; methylated in the 





The pattern of hemi-methylated or methylated versus unmethylated throughout the DAX-1 
promoter is increasingly evident following the MSRE analysis (Table 2.2). Overall, the A549 lung 
carcinoma cells, HeLa cervical adenocarcinoma cells, and the SW13 adrenal gland carcinoma cells 
exhibited the lowest degree of methylation in the DAX-1 promoter region. The remaining 
cancerous cell lines, Hep-3B hepatocellular carcinoma and MCF7 breast cancer, were at least 
hemi-methylated at each amplified region containing a minimum of one CCGG CpG island. 
Surprisingly, the MCF10A control, noncancerous cell line was also consistently methylated or 
hemi-methylated in the DAX-1 promoter region.   
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Table 2.2. Summary of MSRE results grouped by cell line and amplified region of the 
promoter. The MCF10A cell line is the control, non-cancerous cell line while the remaining cell 






The RNA and protein level analyses confirmed DAX-1 expression varies between the 
different types of cancer cell lines analyzed. The highest level of DAX-1 expression at both the 
RNA and protein levels was found in lung and adrenal carcinomas. Conversely the lowest 
expression was detected in the metastatic breast cancer cell line. To further test the hypothesis that 
expression may be decreased due to methylation of CpG islands, methylation specific restriction 
enzyme analysis was used as a crude quantification of the degree of methylation of CpG islands 
in the promoter region of the DAX-1 gene. Comparing these expression based results to the crude 
assessment of methylation status of CpG islands within the promoter region, methylation is greater 
in the cell lines that expressed low levels of DAX-1. Notably, the MCF7 breast cancer and Hep-
3B hepatocellular carcinomas were hemi-methylated or methylated at each amplified region 
containing a minimum of 1 CCGG CpG island. Furthermore, amongst the cancerous cell lines the 
highest expressor of DAX-1 at both RNA and protein levels was the A549 lung carcinoma and no 
methylation was observed with MSRE analysis. The SW13 adrenal carcinoma was also a high 
expressor of DAX-1 based on the qPCR and western blot experiments, but the methylation status 
of the CpG island furthest upstream could not be determined with confidence with MSRE. The 
two interesting outliers following the first set of experiments are the MCF10A noncancerous cells 
and the HeLa cervical adenocarcinoma cells. Although the MCF10A showed average levels of 
DAX-1 at the RNA level, at the protein level a product was barely visible. Furthermore, the MSRE 
revealed the DAX-1 promoter is hemi-methylated or methylated throughout in the MCF10A 
noncancerous cell line. This may be due to the irregular behavior and the role of DAX-1 
occasionally observed mammary cells (Judge, 2011). While the cause of this variability is 
unknown, it may be linked to cell growth conditions such as cell density. Indeed, it has been well 
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documented that there is a heterogeneity and variability in the MCF7 cell line, although it continues 
to be one of the most widely studied human breast cancer cell line (Lee et al., 2015, p. 7). In 
contrast the HeLa cells expressed low levels of DAX-1 at the RNA level, but DAX-1 was 
abundantly expressed at the protein level. This incongruity between DAX-1 expression levels in 
RNA versus protein may be the result of translational regulation, where translation is not directly 
related to transcription (Kelen et al., 2009). The RNA and protein data from the HeLa cancer cell 
line aligned with the MSRE analysis results from the lung and adrenal carcinoma cell lines, 
revealing a lack of methylation in each amplified region. This could indicate that an alternative 
means of translational regulation is controlling DAX-1 expression in HeLa cervical 
adenocarcinoma cells.  
Ultimately, the results of these experiments confirmed that DAX-1 is differentially 
expressed across multiple human cancer cell lines and that methylation patterns correlate with 
some of this variation. These results also narrowed down which cell lines are likely exhibiting 
regulation of DAX-1 expression via methylation as well as where the critical methylation site is 
located in the promoter region. The first CpG island located nearest to the 5’ end of the promoter 
region, and upstream from the transcriptional start site TATA box, was determined to be the most 
critical island for further investigation. This evaluation was based on the results of the MSRE 
analysis which demonstrated significant variation in methylation status across all six cell lines at 
this CpG island, and was further supported by literature highlighting the importance of CpG islands 
at the 5’ end of the promoter (Cross & Bird, 1995; Janitz & Janitz, 2011; Sleutels & Barlow, 2002) 
Bisulfite sequencing was determined to be the best means to elucidate whether this CpG island is 
protected via methylation in three cells line: A549 lung carcinoma – the highest expressor of the 
DAX-1 at both RNA and protein levels with the least amount of methylation, MCF7 – the lowest 
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expressor of DAX-1 that was methylated in the promoter, and MCF10A – the noncancerous cell 




Chapter 3: Identification of methylated CpG islands in the DAX-1 promoter 
Introduction 
The second aim of this project was to identify the CpG islands that are methylated in the 
DAX-1 promoter. Specific focus was targeted on CCGG sequences surrounding the transcriptional 
start site and TATA box. This aim was accomplished via bisulfite sequencing, where bisulfite 
conversion and sequence analysis were carried out on the lung carcinoma cell line (A549), the 
breast carcinoma cell line (MCF7), and the control (MCF10A), immortalized mammary gland cell 
line. These three cell lines were selected based on the results of the DAX-1 expression and MSRE 
analyses. The A549 cell line exhibited the highest RNA and protein level expression of DAX-1 
and had the least amount of methylation in all five CpG rich regions in the promotor. Alternatively, 
the MCF7 cell line consistently showed the lowest level DAX-1 expression and had one of the 
highest degrees of methylation in all five regions of the promoter. The MCF10A cell line was 
included as a control and counterpart to the breast cancer cells.  
Bisulfite sequencing is the gold standard for determining the methylation status of gDNA 
(L. C. Li & Dahiya, 2002; Wreczycka et al., 2017; Zymo Bisulfite Converted DNA Amplification 
Guide, 2015). After gDNA is isolated, it is treated with sodium bisulfite, which deaminates 
unmethylated cytosines to uracil. The converted UG regions are isolated using amplification and 
directly sequenced with Sanger Sequencing (Figure 3.1). Bisulfite treatment does not deaminate 
methylated cytosines, which are protected by methylation and remain as cytosines during DNA 
sequencing. Therefore, the location of methylated cytosines is determined by comparing DNA 
sequence analysis of bisulfite treated and untreated samples. By introducing site specific changes, 





Figure 3.1 Methodology of bisulfite conversion. Bisulfite sequencing allows for the precise 
determination of methylation status in the genome. During bisulfite modification, unmethylated 
cytosines are deaminated and converted to uracils. Therefore, after amplification and sequencing 





In conjunction with results from bisulfite sequencing, chromatin immunoprecipitation 
(ChIP) was utilized in order to build a model of methyl binding protein occupancy in the two 
mammary cells lines. This approach was central to the identification of the methylating proteins 
occupying the DAX-1 promoter region and to which CpG islands they are binding. There are two 
primary families of proteins that directly interact with methylated DNA: DNA Methyltransferases 
(DNMTs) and Methyl-CpG-Binding Proteins (MBPs) (L. Li et al., 2015).  
DNMTs catalyze the transfer of a methyl group to 5’ cytosines. However, DNMTs are 
essential to cell division and growth and therefore are a challenging target to use in narrowing 
down methylation location via methylation modifying proteins. The second family, MBPs, are 
composed of three sub-groups of proteins: Set and Ring Associated (SRA) domain proteins, Kaiso 
and Kaiso-like proteins, and Methyl-CpG-Binding Domain proteins (MBD) (Sasai et al., 2010).  
SRA domain proteins bind to methylated CpG islands and are observed in plants and 
animals. However, they perform a diverse range of functions beyond methylation and have been 
shown to bind methylated cytosines that are not part of CpG island in plants (Fournier et al., 2012). 
Due to their diverse role and ability to bind any cytosine, this family of proteins is not as pertinent 
to the investigation of specific CCGG CpG methylation.  
The Kaiso and Kaiso-like family of proteins are an active field of research. First identified 
as DNA-binding factors, these proteins can serve as transcriptional repressors when bound to 
methylated CpG islands. Kaiso proteins are unique in their ability to also bind specific target 
sequences (Fournier et al., 2012). However, Kaiso and Kaiso-like proteins can also bind to regions 
not containing CpG islands, as well as regions containing a CpG island that cannot be methylated. 
Due to their diverse occupancy, these are not a viable set of proteins for the aim of this project.  
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Finally, Methyl-CpG binding proteins (MBP) or methyl-CpG binding domain proteins 
(MBD proteins) are key regulators of repressed gene expression and recruit other epigenetic 
regulators (Fournier et al., 2012; MBD1 Antibody (Clone 100B272.1), n.d., p. 1). Though this 
protein family is large, consisting of eleven different proteins categorized further into three sub-
groups, the MBD sub-group of proteins have non-overlapping functions and bind to symmetrically 
methylated CpG islands (Roloff et al., 2003). Furthermore, this protein family is known for their 
role in epigenetic regulation and binding DNA with symmetrically methylated CpG islands 
(Fournier et al., 2012; Hendrich & Tweedie, 2003; Roloff et al., 2003). Surveying various members 
of the family illuminates their unique roles. MBD1 and MBD2 bind to methylated DNA, while 
MBD3 does not (Fournier et al., 2012). Interestingly, while MBD1 occupies both methylated and 
non-methylated regions and therefore should bind indiscriminately, it has an affinity for 
unmethylated DNA (L. Li et al., 2015). MBD1 can also recruit other methylating proteins and 
form a complex that methylates the DNA and represses transcription (L. Li et al., 2015). MBD2 is 
a transcriptional repressor and along with HDAC, will package gDNA into inactive chromatin. 
Therefore, areas in which MBD2 binds are likely regions in which DAX-1 is being repressed. 
Finally, MBD3 forms a complex with HDAC in regions containing 5-hydroxymethyl cytosine 
methylation. In addition to interacting with HDAC and colocalized DNMTs, when MBD2 and 
MBD3 form dimerized complexes, they have an increased affinity to hemi-methylated DNA 
regions (Tatematsu et al., 2000). The diverse roles each of these methylating proteins play in 
epigenetic regulation and DNA binding can be utilized to clarify specific methylation status in the 





Figure 3.2 Summary of MBD proteins mechanism for repressing transcription. Adapted from 
L. Li et al., 2015 and Liyanage et al., 2014, MBD1 and MBD2 bind to methylated promoters and 
repress transcription. (TRD: transcription repression domain found with MBD1 and MBD2 
repressed regions). MBD3 cannot bind to methylated regions, however, it can recruit other 





Materials and Methods 
Bisulfite treatment 
Thermo Scientific EpiJet Bisulfite Conversion Kit (REF: K1461) was used after literature 
review revealed this kit is one of the premier bisulfite treatments available, preserving the integrity 
of the gDNA more so than other commercially available kits (Brouwer, 2013; Darst et al., 2010; 
L. C. Li & Dahiya, 2002; Schock & Traeger, 2011; Tierling et al., 2018; Worm Ørntoft et al., 
2017; Wreczycka et al., 2017; Zymo Bisulfite Converted DNA Amplification Guide, 2015). 
Optimized results were achieved through Protocol A, the ‘long protocol’, as it had a higher DNA 
conversion frequency (>99% versus >95%) and a lower degradation frequency. Modifying 
reagents were added to purified and quantified gDNA. Following bisulfite conversion, the 
modified gDNA was cleaned and desulphonated before amplification with PCR (Table A.1; 
Appendix A).  
 Primers were designed with the recommended EpiDesigner bisulfite modified primer 
software and were initially optimized using a temperature gradient for PCR, as well as minor 
adjustments to the PCR protocol (EpiDesigner, 2017). The primers for bisulfite sequencing 
amplified the region encompassing the first CCGG CpG island upstream from the TATA box 
(Table A.2; Appendix A). A slightly larger region was amplified than previously seen in the 
MSRE since sequencing often results in degraded base pairs at the beginning and end of the 





Figure 3.3 The DNA sequence of DAX-1 promoter region with bisulfite primers. The primers 
amplify the region nearest the transcriptional start site, specifically targeting the CpG island prior 
to the TATA box.   
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Bisulfite primers were first tested on a survey of gDNA to ensure optimized amplification 
by PCR regardless of the timeframe in which the gDNA was isolated. Assessing the result of 
bisulfite modification on previously isolated gDNA, gDNA taken from a preserved cell pellet, and 
gDNA purified from recently lifted cells have similar relative levels of amplification (Figure 3.4). 
However, the gDNA from the cell pellet gave the most robust amplification and therefore this 





Figure 3.4 Comparison of source of gDNA used for bisulfite modification. Multiple bisulfite 
primers were tested in A549 bisulfite converted gDNA to compare quality of PCR product 
depending on different isolation sources. Shown in each set of six lanes are different primer sets 
isolating various regions of the DAX-1 promoter that correspond with regions segmented for the 
methylation specific restriction enzyme analyses. Water control samples (lanes 19-24) resulted in 





Amplification via PCR was repeated for a total of three times, where the input for the 
second and third rounds was 4µL of PCR product from the previous cycle. Following the third and 
final PCR, 18µL of product was electrophoresed through a 2% agarose gel. The appropriately sized 
PCR product was isolated from the gel, melted, and purified with the Wizard® SV Gel and PCR 
Clean-Up System (REF: A9281, Promega). The resulting purified PCR product was cloned 
directly into the pGEM T Easy plasmid (Promega) using the pGEM®-T Easy Vector System 1. 
Following a 2 hour ligation at room temperature, the ligated product was transformed into 
competent DH5a cells (One Shot®OmniMAX™, Invitrogen) and transformants were selected by 
plating on LB agar plates containing ampicillin (100 µg/mL final concentration). After an 
overnight incubation at 37˚C, 10 well isolated colonies were selected and transferred to LB 
ampicillin liquid cultures to grow overnight at 37˚C with shaking at 250rpm. The following day, 
plasmid DNA was purified from the bacterial cultures using the PureYield™ Plasmid Miniprep 
System (Promega, REF A1222).  
To confirm the correct product had been isolated and successfully cloned into pGEM-T 
Easy, 5µL of the 25µL miniprep yield was used as input into a restriction digest reaction. Enzyme 
volumes were between 0.3µL and 0.5µL per 10µL sample, with 1µL of corresponding NEB buffer, 
and nuclease free water. Enzymes were chosen based on the pGEM-T Easy vector map (Figure 
3.5). Restriction digest reactions were incubated overnight at 37˚C and analyzed the following day 
by adding 2 µL Gel Loading Dye Purple (6x) (New England Biolabs #B7024S) prior to 





Figure 3.5 pGEM®-T Easy Vector map. Acquired from Promega pGEM®-T Easy Protocol 
(Promega, 2018). Corresponding enzymes used for the restriction digest were selected from this 




Enzymes and corresponding buffers were utilized in the following restriction digest 
reactions: Apa1 with Nde1 and Not1 with BstX1 (New England Biolabs, Inc). Only plasmids that 
released a band corresponding to the PCR product size were submitted for DNA sequence analysis 
(Molecular Cloning Laboratories) using M13 forward and reverse primers (Figure A.1). Control 
sequences of non-bisulfite modified gDNA from each of the cell lines were sequenced using the 
same amplification and isolation protocol to confirm DNA sequences match to known wildtype 
DAX-1 sequences from NCBI. 
Sequence products were analyzed manually and confirmed by Clustal Omega alignments 





Following the determination of differential methylation status of CpG islands in the DAX-
1 promoter, it was important to understand the mechanism of this epigenetic regulation. 
Specifically, determining the identity of the methylating proteins that were likely mediating 
changes in the methylation status of the DAX-1 gene was essential in order to elucidate the 
mechanism. To address this, chromatin immunoprecipitation (ChIP) assays were carried out using 
the MCF7 (breast cancer) and MCF10A (mammary gland immortalized) cell lines. ChIP assays 
provide a means to isolate proteins that are physically bound to the CpG island sites in the DAX-1 
promoter and exon 1, indicating their direct association with the DAX-1 epigenetic regulatory 
region. Antibodies directed against known methylating proteins were used in the ChIP assays 
allowing determination of whether a particular epigenetic regulatory protein is associated with the 
DAX-1 promoter and/or exon 1 region. Subsequent PCR analysis allows for the correlation of 
protein binding to a specific DNA region. ChIP can be used to specifically target methylating 
proteins associated with the silencing of gene expression (Fuks et al., 2003; Viré et al., 2006). The 
same primer sets utilized in Chapter 2 for the methylation specific restriction enzyme analysis were 
also used in the ChIP assays. 
ChIP assays were carried out using the ab500-ChIP kit (Abcam). Sonication of cross-linked 
chromatin was performed by water bath sonication using a Misonix S-4000 sonicator in order to 
fragment the chromatin into smaller pieces. The optimal size of sonicated chromatin should be 
between 200 and 1000 base pairs. Sonication time was optimized by analyzing genomic DNA 
fragment size after 5 minutes, 7 minutes, and 10 minutes of 30 second intervals. The resulting 
DNA products were electrophoresed through a 2% agarose gel (Figure 3.6). Through these 




Figure 3.6 Comparison of different chromatin sonication times in the cancerous MCF7 and 
control MCF10A cell lines. Alternating 30 seconds shear and 30 seconds off, optimized 
chromatin product size was produced after 7 minutes of sonication. Ideal fragment size is between 




Control ChIP reactions included non-crosslinked sheared chromatin samples that underwent 
all other experimental conditions. Positive ChIP reactions included immunoprecipitations using 
the HDAC antibody. Sheared chromatin that did not undergo further experimental conditions was 
included as an “input” control. After sonication, sheared chromatin was diluted in buffer and 3µg 
of the following antibodies were added for crosslinking: 
● anti-MBD1 (methyl-CpG binding domain protein 1), rabbit polyclonal,   
 abCam (catalog # ab2846-100) 
● anti-MBD2a (methyl-CpG binding domain protein 2), rabbit polyclonal,   
 abCam (catalog # ab3754-100) 
● anti-MBD3 (methyl-CpG binding domain protein 3), rabbit polyclonal,   
 abCam (catalog # ab3755-100) 
● anti-HDAC3 (histone deacetylase), rabbit polyclonal,     
 abCam (catalog # ab47237) 
 
Reactions were incubated at 4˚C with rotation overnight prior to clean-up. A 50% slurry of 
Protein A agarose beads was used to purify the antibody/chromatin product along with the 
recommended number of wash steps. Maximum input of the final cross-linked and purified product 
was used as a template for PCR amplification. Finally, reaction products were electrophoresed 
through a 2% agarose gel stained with ethidium bromide. Based on the presence or absence of a 
product following PCR amplification, a model of protein occupancy throughout the promoter 





Sequence analysis of control, non-bisulfite modified sequences aligned with NCBI NR0B1 
gene sequence in the non-cancerous MCF10A breast cell line and lung carcinoma A549 cell line 
(Figure 3.7). Although the MCF7 amplicon is consistent with the primers designed to segment the 
region surrounding the TATA box and first CpG island, the results were not included alongside 
the MCF10A and A549 initial alignment shown in Figure 3.7. Unfortunately, while the MCF7 
breast cancer non-bisulfite modified product was still within the DAX-1 gene, the amplicon 
showed a different sequence. Across multiple biological replicates with ten clones each, all 
resulted in successful primer alignment and had the same amplicon region (Figure A.2; Appendix 
A). This difference in MCF7 sequence results could be due to the previously discussed 
heterogeneity and variability well documented by other researchers (Lee et al., 2015). 
Furthermore, when entered into BLAST (NCBI BLAST, n.d.) these sequences matched the NR0B1 
gene, confirming that we were analyzing the DAX-1 gene in MCF7 cells and could continue with 





Figure 3.7 Sequence alignment of DAX-1 promoter region. Sequence alignment comparison of 
the control, non-bisulfite converted MCF10A and A549 cell lines to the NCBI sequence. The 
clonal sequences tested had a high rate of similarity (Figures A.2, A.3, and A.4; Appendix A). 
MCF7 data is not shown on this alignment due to slightly different amplicon falling between these 




In comparison, the bisulfite treated data was heavily degraded and was more challenging 
to align. A crude alignment did show successful conversion of most cytosines to uracil (Figure 
3.8). Within this region, each cytosine not protected by a methyl group was converted to a uracil, 
reading as a thymine in the final DNA sequence analysis. This selected area demonstrates the 
power of bisulfite conversion in unmethylated sequences. Furthermore, as this region is early in 
the sequence, this data confirms each of the three cell lines were successfully bisulfite modified 






Figure 3.8 Sequence alignment of deaminated cytosines in DAX-1 promoter region of 
bisulfite modified DNA. Highlighting the successful alignment and conversion of unmethylated 




 Highlighting a second region in the bisulfite modified sequence that follows the CCGG 
CpG island and TATA box demonstrates the protection of certain cytosines (Figure 3.9). Cytosine 
methylation can occur at non CCGG CpG islands as well as independent cytosine residues. These 




Figure 3.9 Sequence alignment of protected cytosines in DAX-1 promoter region of bisulfite 
modified DNA. Not all cytosine residues are deaminated within the gDNA. Those that are not 




 Refining the focus to the specific CCGG CpG island of interest, differential conversion is 
observed (Figure 3.10). Although the bisulfite modification severely damages the sequence in 
certain places, an alignment can be identified based on specific base pairs. Overall, the least 
degraded sequence came from the MCF10A noncancerous control cell line. Aligning this sequence 
as best as possible against the NCBI wild type allowed for a clear alignment of the two cancerous 
cell lines. Systematically looking at the CCGG sequence, this CpG island in the MCF10A cell line 
is likely, this CpG island is hemi-methylated and therefore only partially protected via methylation. 
The MCF7 breast cancer cells produced the most degraded sequence, in line with expectation from 
previous research on the irregularities observed in breast cancer and DAX-1 expression. When 
taking into account the preservation of both guanines and the successful conversion of one cytosine 
to thymine, this island is likely hemi-methylated and mostly protected. Finally, this CpG island in 






Figure 3.10 Sequence alignment of CpG island in the DAX-1 promoter region of bisulfite 
modified DNA. Highlighted in purple and gray are the regions used to identify the CpG island in 
the bisulfite modified gDNA. The pink region indicates the CCGG CpG island being investigated 





Taking into consideration the size of the target region being amplified, a band of correct 
molecular weight indicates the presence of the methyl-CpG binding domain protein at the CpG 
islands located within the amplified regions. Honing in on protein occupancy in Region B located 
shortly after the transcriptional start site, none of the MBD proteins were found to occupy the three 
CpG islands located in this area of the DAX-1 promoter in the control MCF10A cell line (Figure 
3.11). Conversely, all three MBD proteins were found in Region A and E, each containing 1 CpG 








Figure 3.11 PCR amplification product following ChIP in MCF10A non-cancerous 
mammary gland control cells. The top row indicates results for MBD1, 2, and 3 binding. Within 




In comparison to the MCF10A ChIP products, the MCF7 products provide much more 
intense bands in some regions, notably in Region B. MCF7 cells demonstrated occupancy by all 








Figure 3.12 PCR amplification product following ChIP in MCF7 breast cancer cells. The top 
row indicates results for MBD1, 2, and 3 binding. PCR products are detected in regions A, B, C, 
and E. Region D only gives faint bands in the control settings indicating that it is not a target of 
the MBD binding family of proteins. 
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 Following analysis of amplified ChIP products, a schematic of MBD protein occupancy 
highlights the difference between control and cancerous breast cell lines (Figure 3.13). Most 
striking is the occupancy of all the MBD proteins in Region B in the cancerous cell line but not 
the control. This region contains three CCGG CpG islands and is located directly after the TATA 
box. The presence of all three MBD proteins and HDAC indicates that this region is being 
repressed via methylation in this cancer cell line (e.g. MCF7 cells, shown in the lower half of the 





Figure 3.13 Model of methyl-CpG binding protein occupancy on the DAX-1 gene in MCF10A 
control and MCF7 breast cancer cell lines. In both cell lines, there is a great deal of occupancy 
by these proteins, however, there is a clear difference when focusing on amplified Region B. 
Located near the TATA box, this region is repressed by MBD1, MBD2, and MBD3 in the breast 







Through bisulfite sequence analysis and chromatin immunoprecipitation, a model of the 
difference between methylation status of CpG islands in the DAX-1 promoter region was 
developed. The A549 cells were heavily modified at the CpG island of interest, concluding that 
this region was not protected via methylation. This aligns with results from Chapter 2 that 
identified this lung carcinoma cell line as the highest expressor of DAX-1 at the RNA and proteins 
levels. Additionally, bisulfite sequencing gave a more precise depiction of what the MSRE analysis 
revealed: the CpG island, located further upstream in the DAX-1 promoter, preceding the TATA 
box, is unmethylated in the A549 lung carcinoma cells. Bisulfite sequencing also revealed that 
MCF7 breast cancer and MCF10A noncancerous mammary gland cells are likely hemi-methylated 
at this CpG island, confirming the results of MSRE analysis from Chapter 2. The hemi-methylation 
in MCF7 cells could be correlated with the decreased expression of DAX-1 at the RNA and protein 
levels previously observed in the first aim. Additionally, methyl-CpG-binding domain protein 
occupancy in this region of the MCF10A DAX-1 promoter determined via ChIP confirmed the 
hemi-methylation status concluded from bisulfite sequencing. Furthermore, ChIP analyses 
highlighted a region following the TATA box where MBD occupancy varies between the 




Chapter 4: Discussion 
The DAX-1 orphan hormone nuclear receptor has been shown to suppress tumor 
progression in cancer metastasis. The hypothesis of this thesis was that DAX-1 gene expression is 
differentially expressed across a survey of various cancers and that differential expression of DAX-
1 was, at least in part, due to the epigenetic repression via methylation. Methylation is a form of 
epigenetic modification that can prevent transcription factors from binding to DNA in the promoter 
region and thereby silencing gene expression. The implementation of qPCR and Western Blotting 
confirmed that DAX-1 is being differentially expressed in the six human cell lines investigated. 
Furthermore, methylation specific restriction enzyme analysis and bisulfite sequencing provided 
evidence of methylation resulting in repressed gene expression. Finally, chromatin 
immunoprecipitation confirmed a difference in methyl protein binding occupancy in cancerous 
versus noncancerous cell types. Interestingly, methylation was also observed in the control cell 
line. Though somewhat surprising, this is not altogether unexpected. The mammary glands are 
composed of a frequently changing cellular landscape and the presence of DAX-1 fluctuates 
(Judge, 2011). Additionally, the control cell line utilized was not ‘normal’ as it was isolated from 
a diseased, but not tumorigenic, tissue. 
Given the role of DAX-1 in mediating sexual determination in humans and regulating 
differentiation of embryonic stem cells, it is not surprising it is epigenetically regulated. Studies 
have shown that proper DNA methylation plays a key role in cell growth and differentiation, as 
well as embryonic development (Iyer & McCabe, 2004; Lalli, 2014; Lalli et al., 1997; McCabe, 
2007). Proper timing of DAX-1 expression is likely, at least in part, epigenetically controlled. 
Previous studies in the Tzagarakis-Foster lab have demonstrated that the reintroduction of DAX-
1 at a physiological level slows the cell proliferation of MCF7 breast cancer cells and tumor 
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formations in mouse xenograft models (Tzagarakis-Foster, manuscript in preparation). 
Extrapolating the results shown in this project suggests that releasing the epigenetic control in a 
cell line may, in turn, slow proliferation in tumor growth.  
Cancer epigenetics is currently a cutting-edge field of research. Specifically, epigenetic 
regulation of nuclear hormone receptors in tumorigenesis, has been the target of investigation for 
new cancer therapies. The role of NHRs in cancer is complex and diverse. However, by targeting 
methyl binding proteins to either release or induce epigenetic regulation of NHR gene expression, 
alternative therapeutic targets may be developed in the future. Additionally, evaluating the degree 
of methylation in tissue samples could be a viable biomarker for cancer screening.  
As a nuclear hormone receptor, DAX-1 may potentially serve as a biomarker for the 
increased likelihood of tumor development and cancer progression. Clinically, DAX-1 has been 
extensively reviewed for its role in Adrenal Hypoplasia Congenita (AHC) and Dosage Sensitive 
Sex reversal (DSS). Combined with its interdisciplinary connections to disease, as well as the rise 
of nuclear hormone receptors, specifically in the orphan family, and methylation status as 
oncogenic biomarkers, further investigation of the role of DAX-1 in hormone regulated cancers 
could lead to future clinical applications. Future research integrating a more in depth bioinformatic 
approach studying the DAX-1 epigenome and patient tissue samples could elucidate the importance 
of DAX-1 in cancer tumor suppression, particularly in breast tissues. Accessing methylation 
specific cancer databases and alignments from patient data against the wild type DAX-1 gene 
would further determine the importance of methylation in the promoter region. Additionally, 
understanding to what extent methylation represses gene expression could give rise to applications 
that would release epigenetic control. In conclusion, the study of methylation status and NHRs 
may uncover novel biomedical and therapeutic approaches to detecting and treating cancer. 
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Appendix A: Supplementary Figures and Tables 
 
Figure A.1 Restriction digest analysis of pGEM-T Easy and converted or control DNA 







Figure A.2 Sequence alignment of A549 bisulfite modified gDNA. Obtained from multiple 






Figure A.3 Sequence alignment of MCF7 bisulfite modified gDNA. There are only minor 
discrepancies (highlighted in yellow) between the multiple bisulfite modified DNA samples 





Figure A.4 Sequence alignment of MCF10A bisulfite modified gDNA. Obtained from multiple 
clones, there are some discrepancies (highlighted in yellow) between the multiple bisulfite 
modified DNA samples. 
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Table A.1 Summary table of PCR running protocol parameters 
Protocol Cycling Parameters 
DAX-1 gDNA Detection via 
PCR 
95˚C x 3 minutes 1 Repeat 
95˚C x 30 seconds 
55˚C x 30 seconds 
72˚C x 1 minute 
Repeat 35 times 
72˚C x 5 minutes 1 Repeat 
4˚C x infinite hold 1 Repeat 
DAX-1 mRNA Expression via 
qPCR 
95˚C x 10 seconds 1 cycle 
95˚C x 15 seconds 
60˚C x 15 seconds 
40 cycles 
Methylation Specific Restriction 
Digest PCR 
95˚C x 3 minutes 1 Repeat 
95˚C x 20 seconds 
61˚C x 30 seconds 
72˚C x 1 minute 
Repeat 32-40 times 
72˚C x 5 minutes 1 Repeat 
4˚C x infinite hold 1 Repeat 
PCR Amplification of Bisulfite 
Converted gDNA 
95˚C x 3 minutes 1 Repeat 
95˚C x 20 seconds 
52.3˚C x 30 seconds 
72˚C x 60 seconds 
Repeat 35 - 45 times 
72˚C x 5 minutes 1 Repeat 
4˚C x infinite hold 1 Repeat 
PCR Amplification on Isolated 
ChIP Products 
95˚C x 3 minutes 1 Repeat 
95˚C x 20 seconds 
61˚C x 30 seconds 
72˚C x 60 seconds 
Repeat 50 times 
72˚C x 5 minutes 1 Repeat 





Table A.2 Summary table of the primers used in PCR and qPCR 
Target Forward Primer Reverse Primer 
Primers to detect genomic 
DAX-1 spanning Exon 1 
(676) to Intron (1251) in 
gDNA: 
5’ - CCC ACG ACA AAT 
CAA GC - 3’ 
5’ - CTG CCC GAT GCT 
TTT GTG AG - 3’ 
Primers to detect 
genomic DAX-1 spanning 
Intron (1232) to Intron (2399) 
in gDNA: 
5’ - CTC ACA AAA GCA 
TCG GGC AG - 3’ 
5’ - GGG GTG AGC TGA 
GGT CTC TAG - 3’ 
 
Primers to detect DAX-1 gene 
expression in qPCR 
5’ - GAC TCC AGT GGG 
GAA CTC AG - 3’ 
5’ - ATG ATG GGC CTG 
AAG AAC AG - 3’ 
Primers to detect GAPDH 
gene expression (positive 
control): 
5’ - CCA TCA CCA TCT 
TCC AGG AGC G - 3’ 
5’ - AGA GAT GAT GAC 
CCT TTT GGC - 3’ 
Primer CpG Rich Region A 
(Used for MSRE and ChIP) 
5’ - GAA GGA GGA AAG 
TGT CCA GGA GCT C -3’ 
5’ - AGC CCA GTT CTG 
CCC AGT GGC TGC C -3’ 
Primer CpG Rich Region B 
(Used for MSRE and ChIP) 
5’ - AGG GCA GCA TCC 
TCT AGA AC - 3’ 
5’ - TCT TCA CCA CAA 
AAG CAG CA - 3’ 
Primer CpG Rich Region C 
(Used for MSRE and ChIP) 
5’ - CTC AAA GCA AAC 
GCA CGT G - 3’ 
5’ - CAC CTG TGG ACT 
CTT GAG CG - 3’ 
Primer CpG Rich Region D 
(Used for MSRE and ChIP) 
5’ - GAA GAC CAC CCG 
CAG CAG - 3’ 
5’ - CAC TTG ATG GCT 
TGG ACC TG - 3' 
Primer CpG Rich Region E 
(Used for MSRE and ChIP) 
5’ - AAT GCT GGA GTC 
TGA ACA TCA GTA CCA 
AGG - 3' 
5’ - CCA CCC CAA CTC 
TGC TGA GTT AGT C - 3' 
Amplification of Bisulfite 
Modified gDNA Region 
Containing TATA Box and 
First CpG Island 
5’ - AAG GAG GAA AGT 
GTT TAG GAG TTT - 3’ 
5’ - TGG AAA GAG TTG 
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